First author, year | Study type | No. of patients | Mean onabotA dose/injection | Duration of effect | Definition of duration | Country of origin |
---|---|---|---|---|---|---|
Mean (±SD) units | Mean (±SD) | |||||
Benecke 2005 [17] | Prospective, randomized, double-blind, parallel-group, noninferiority study | 232 | 138.9 ± 46.8 | 94.3 ± 31.4 days | Interval between injection and first visit at which TWSTRS severity score reached 80% of baseline | Ex-US |
Bihari 2005 [6] | Prospective, single-arm, crossover study | 12a | 131 | 64.3Â days | Time to reach 70% TWSTRS score | Ex-US |
Brashear 2005 [3] | Retrospective | 172b | 241.80-254.07 | 108.48Â days (year 1) | Interval between treatments | US |
Brashear 2000 [25] | Retrospective | 60 | 263 | 15.5 ± 3.4 weeks | Interval between visits | US |
Brashear 1998 [27] | Prospective, single-center study | 149c | 219.8 ± 63.5 | 142.9 ± 85.8 days | Average time between treatments | US |
Brin 2008 [29] | Prospective, open-label, multicenter study | 326 | 187.0 ± 76.5 | 110.2 ± 91.8 days | Time from treatment injection to date of next injection | US/Ex-US |
Brockmann 2012 [24] | Retrospective | 20 | 175 ± 76 | 10.7 ± 1.9 weeks | Time between last treatment and first subjective notice of reduction of benefit from the treatment | Ex-US |
Camargo 2008 [18] | Prospective, single-center study | 85 | 151.05 ± 52.55 | 89.1 ± 21.8 days | Patient-reported time to return of symptoms | Ex-US |
Dubinsky 1991 [28] | Prospective cohort | 84 | 269 ± 39 | 107 ± 49 days | Time from initial injection until patient-reported worsening of symptoms | US |
Jankovic 2003 [19] | Prospective, single-center study | 119 | 223.9 ± 73.0 | 14.6 ± 5.6 weeks | Not specified | US |
Jankovic 1990 [26] | Prospective cohort | 205 | 105.4 ± 33.8 | 14.0 ± 6.9 weeks | Duration of peak effect | US |
Maia 2010 [20] | Retrospective | 67 | 204.79 | 13.01Â weeks | Duration which patient had any benefit from treatment | Ex-US |
Meija 2005 [21] | Retrospective | 16d | 221.2 ± 129.4 | 15.4 ± 3.4 weeks | Not specified | US |
Mohammadi 2009 [7] | Prospective cohort | 44 | 145 ± 44 | 10 ± 2.4 weeks | Not specified | Ex-US |
Naumann 2002 [8] | Prospective, randomized, double-blind, crossover study | 59 | 155 ± 51 | 13.9 ± 2.6 weeks | Time to TWSTRS severity score ≥10 and rotational score ≥1 | Ex-US |
68 | 157 ± 44 | 13.6 ± 2.4 weeks | ||||
Odergren 1998 [22] | Prospective, randomized, double-blind, parallel-group study | 35 | 152 ± 45 | 80.7 ± 14.4 days | Time to retreatment | Ex-US |
Quagliato 2010 [30] | Prospective, randomized, double-blind study | 12e | NR | 11.7 ± 3.4 weeks | Interval between day of treatment and patient-reported waning effect | Ex-US |
Ranoux 2002 [23] | Prospective, randomized, double-blind, crossover study | 51 | 104.4 ± 20.6 | 89.1 ± 19 days | Interval between day of treatment and patient-reported waning of effect | Ex-US |